In addition to the approval for the standard treatment for Ex20ins-mutant NSCLC, amivantamab–lazertinib treatment has shown efficacy and safety as a first-line treatment of advanced EGFR-mutant NSCLC compared with osimertinib monotherapy in the MARIPOSA trial [32]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.